• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

1.700 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
December 05, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
December 01, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
November 18, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For October 30, 2025 ↗
October 30, 2025
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
August 07, 2025
 
Via Benzinga
News headline image
INMUNE BIO INC (NASDAQ:INMB) Reports Narrower-Than-Expected Q3 2025 Loss ↗
October 30, 2025
INmune Bio (INMB) reported a narrower-than-expected Q3 2025 loss, sparking a positive after-hours market reaction for the clinical-stage biotech firm. 
Via Chartmill
News headline image
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
October 23, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
October 14, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
September 29, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
September 15, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio (INMB) Q2 Loss Widens 110% ↗
August 07, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
August 07, 2025
 
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
August 04, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
August 04, 2025
 
Via Benzinga
News headline image
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
August 04, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
July 31, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
July 29, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
July 28, 2025
 
Via Benzinga
News headline image
INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge? ↗
July 28, 2025
Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday. 
Via Benzinga
News headline image
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference
July 24, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday ↗
July 04, 2025
Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge. 
Via Benzinga
News headline image
Which stocks have an unusual volume on Thursday? ↗
July 03, 2025
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
News headline image
This Textron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
July 01, 2025
 
Via Benzinga
News headline image
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 30, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
June 30, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Crude Oil Moves Lower; Joby Aviation Shares Surge ↗
June 30, 2025
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
June 30, 2025
 
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
June 30, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain ↗
June 30, 2025
INmune Bio's Alzheimer's drug XPro showed targeted benefits in patients with brain inflammation, but misses the main trial endpoint. 
Via Benzinga
News headline image
Dow Gains Over 100 Points; Chicago PMI Weakens In June ↗
June 30, 2025
 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap